In vivo hypothalamic release and synthesis of catecholamines in spontaneously hypertensive rats.
Juvenile spontaneously hypertensive rats (SHR) have higher plasma levels of catechols and markedly larger catechol responses to yohimbine than do normotensive Wistar-Kyoto rats, indicating increased sympathoadrenal outflow and increased alpha 2-adrenergic receptor-mediated restraint of peripheral catecholamine release during hypertension development in SHR. Yohimbine-induced catecholamine release and metabolism in the posterolateral hypothalamus of the brain were assessed in juvenile (6 to 7 weeks) and adult (15 to 16 weeks) SHR and Wistar-Kyoto rats. In vivo microdialysis was used to obtain samples for measurements of norepinephrine, dihydroxyphenylglycol, methoxyhydroxyphenylglycol, and dihydroxyphenylacetic acid in conscious animals before and after yohimbine injection (1 mg/kg IV) beginning 24 hours after probe implantation. Catecholamine synthesis was examined from elevations of 3,4-dihydroxyphenylalanine levels after probe perfusion with NSD-1015, an inhibitor of L-aromatic acid decarboxylase. In adults, SHR had higher dialysate norepinephrine (277 +/- 38 versus 181 +/- 35 pg/mL), dihydroxyphenylglycol (3260 +/- 509 versus 2231 +/- 201 pg/mL), methoxyhydroxyphenylglycol (2659 +/- 369 versus 1890 +/- 144 pg/mL), and dihydroxyphenylacetic acid (46,312 +/- 5512 versus 13,187 +/- 1963 pg/mL) levels and markedly larger increases in 3,4-dihydroxyphenylalanine levels after NSD-1015 than Wistar-Kyoto rats. In juveniles, SHR had larger proportionate increments in microdialysate norepinephrine levels after yohimbine than Wistar-Kyoto rats (85% versus 25%). Although juvenile SHR and Wistar-Kyoto rats had similar NSD-1015-elicited increments in 3,4-dihydroxyphenylalanine levels, systemic yohimbine enhanced the NSD-1015-elicited 3,4-dihydroxyphenylalanine elevations in juvenile SHR but not in Wistar-Kyoto rats. These findings suggest augmented norepinephrine release and catecholamine synthesis in the posterolateral hypothalamus of adult SHR and augmented alpha 2-adrenergic receptor restraint of both norepinephrine release and catecholamine synthesis in juvenile SHR.
Pacák
K
K
Clinical Neuroscience Branch, National Institute of Neurological Disorders and Stroke, Bethesda, Md. 20892.
Yadid
G
G
Jakab
G
G
Lenders
J W
JW
Kopin
I J
IJ
Goldstein
D S
DS
D000375:Aging / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000502:physiology; D002395:Catecholamines / Q000378:metabolism*; D002396:Catechols / Q000378:metabolism; D003956:Dialysis; D004295:Dihydroxyphenylalanine / Q000378:metabolism; D006834:Hydrazines / Q000494:pharmacology; D006973:Hypertension / Q000378:metabolism*; D007031:Hypothalamus / Q000378:metabolism*; D007267:Injections; D008297:Male; D009994:Osmolar Concentration; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D015016:Yohimbine / Q000494:pharmacology
D002395:Catecholamines; D002396:Catechols; D006834:Hydrazines; D015016:Yohimbine; D004295:Dihydroxyphenylalanine; C004297:3-hydroxybenzylhydrazine